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Several derivatives of human immunodeﬁciency virus type 1 (HIV-1) that evade macaque restriction
factors and establish infection in pig-tailed macaques (PtMs) have been described. These monkey-tropic
HIV-1s utilize CXCR4 as a co-receptor that differs from CCR5 used by most currently circulating HIV-1
strains. We generated a new monkey-tropic HIV-1 carrying env from a CCR5-tropic subtype C HIV-1
clinical isolate. Using intracellular homologous recombination, we generated an uncloned chimeric virus
consisting of at least seven types of recombination breakpoints in the region between vpr and env. The virus
increased its replication capacity while maintaining CCR5 tropism after in vitro passage in PtM primary
lymphocytes. PtM infection with the adapted virus exhibited high peak viremia levels in plasma while the
virus was undetectable at 12–16 weeks. This virus serves as starting point for generating a pathogenic
monkey-tropic HIV-1 with CCR5-tropic subtype C env, perhaps through serial passage in macaques.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Nonhuman primate models with human-like immune systems
are often employed to evaluate the efﬁcacy of candidate vaccines
against acquired immune deﬁciency syndrome (AIDS). However,
human immunodeﬁciency virus type 1 (HIV-1) infects humans or
chimpanzees (Pan troglodytes) but not rhesus macaques (Macaca
mulatta), the most widely used primate species in biomedical
research (Gibbs et al., 2007). Experimental infection of macaques
with simian immunodeﬁciency virus (SIV) or simian-human
immunodeﬁciency virus (SHIV) has been used extensively to
investigate HIV-1 infection in vivo. Pathogenic infection with SIV
allows insight into the mechanisms of pathogenesis and provides
information for development of novel vaccination strategies.
However, due to the marked antigenic difference in viral proteins
between HIV-1 and SIV, macaque models with SIV are not suitable
for evaluating the immune response directed against HIV-1
(Javaherian et al., 1992; Kanki et al., 1985; Murphey-Corb et al.,
1986). SHIV, a chimeric virus carrying tat, rev, vpu and env from
HIV-1 with an SIV genetic backbone, has been constructed and
used widely to assess the immune response and pathogenicity
directed against HIV-1 Env (Shibata and Adachi, 1992; Reimann
et al., 1996; Harouse et al., 1999)
Highly pathogenic SHIV irreversibly depletes circulating CD4þ
T-lymphocytes, and cause rapidly AIDS-like symptoms in infected
macaques. These properties are, however, different from the vast
majority of circulating HIV-1 or SIV isolates, and the discrepancy
would be attributed to the viral co-receptor preference (Nishimura
et al., 2004). Entry of HIV-1 into cells is mediated through the
interaction of viral envelope protein with cellular CD4 and sub-
sequent binding to either the CCR5 or CXCR4 chemokine receptor
or both receptors. The vast majority of HIV-1 clinical isolates
preferentially utilize CCR5 as the co-receptor for entry (Choe
et al., 1996). The CXCR4-tropic or dual-tropic viruses that utilize
both CCR5 and CXCR4 emerge during late stages in the disease
course (Doranz et al., 1996; Feng et al., 1996).
In addition to the co-receptor usage, it is necessary to consider
the variation of env gene in SHIV construction. Most HIV-1 strains
currently circulating belong to group M, consisting of subtypes
A–D, F–H, J, K and their recombinants, and are largely responsible
for the global AIDS pandemic (Hemelaar, 2012). Most of early
SHIVs are generated by utilizing genes derived from subtype B
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viruses, which comprise an estimated 11% of the global prevalence
of HIV-1. By contrast, subtype C is the dominant subtype, account-
ing for almost 50% of global infections. Subtype C viruses do not
share the antigenicity of Env as the main target of neutralizing
antibodies with subtype B viruses (Choisy et al., 2004; Gaschen et
al., 2002). The V3 loop region of the subtype C envelope is less
variable than that of other subtypes (Kuiken et al., 1999), and
mutations appear to accumulate in the C3 and V4 regions, which
are targets of autologous neutralizing antibody responses in
individuals infected with subtype C viruses (Moore et al., 2008,
2009). The structure of these epitopes is dissimilar between
subtypes B and C (Gnanakaran et al., 2007). There are pathogenic
SHIVs that encode CCR5 tropic subtype C env gene (Ndung’u et al.,
2001; Ren et al., 2013; Song et al., 2006).
Conventional SHIV that encodes SIV sequence in 50 half of the
genome has limited utility in the evaluation of cell-mediated
immunity induced by a vaccine because it does not contain
HIV-1 Gag in its genome; consequently, SHIV has different major
epitopes for cytotoxic T lymphocytes (CTLs) known to be asso-
ciated with lowering the plasma viral load in HIV-1 infection
(Goulder and Watkins, 2004; Kiepiela et al., 2007). Recently, two
major restriction factors were reported to block HIV-1 replication
in monkey cells in a species-speciﬁc manner (Neil and Bieniasz,
2009). The restriction factor apolipoprotein B mRNA-editing
enzyme-catalytic polypeptide-like 3G (APOBEC3G) protein is
incorporated into viral particles and induces hypermutation in
proviral DNA in target cells mediated by its cytidine deaminase
activity (Sheehy et al., 2002). Macaque APOBEC3G proteins are
counteracted by the SIV Vif protein but not by HIV-1 Vif (Mariani
et al., 2003). The other major restriction factor that inhibits the
viral replication cycle is tripartite motif 5α (TRIM5α) protein,
which directly recognizes incoming viral capsid (CA) (Stremlau
et al., 2004). HIV-1 CA can bind cyclophilin A (CypA), a ubiquitous
cytosolic protein, to evade restriction by human TRIM5α, whereas
the CypA-binding activity appears to enhance TRIM5α recognition
in macaque cells (Berthoux et al., 2005; Keckesova et al., 2006;
Stremlau et al., 2006). It is known that the host species barrier of
Pig-tailed macaques (PtMs) (Macaca nemestrina) against HIV-1 is
weaker than other macaques because they do not have the TRIM
restriction (Brennan et al., 2008).
Based on these ﬁndings, derivatives of HIV-1 that has a
remarkably different structure from the conventional SHIV were
constructed by the introduction of minor genetic modiﬁcations
into its genome to overcome the restriction factors in macaque
cells. Hatziioannou et al. (2006) generated simian-tropic HIV-1
(stHIV-1) by replacing the entire vif gene of HIV-1 with that of
SIVmac or HIV type 2. Kamada et al. (2006) reported the monkey-
tropic HIV-1 (HIV-1mt) NL-DT5R, in which the CypA-binding motif
of the CA protein is substituted by the corresponding sequence of
SIVmac, and the entire vif gene is also substituted. Thippeshappa
et al. (2011) generated HSIV-vif, a clone of HIV-1 by substituting
the vif gene with that of a pathogenic SIVmne clone. These
derivatives of HIV-1 established persistent infection in PtMs for
months but were controlled thereafter (Hatziioannou et al., 2009;
Igarashi et al., 2007; Thippeshappa et al., 2011). These monkey-
tropic HIV-1 derivatives currently available are not CCR5-tropic;
NL-DT5R and HSIV-Vif encode env from a CXCR4-tropic, and stHIV-1
encodes env from dual-tropic subtype B viruses.
In this study, we generated a new HIV-1mt strain carrying env
from a CCR5-tropic subtype C HIV-1 clinical isolate. We employed
intracellular homologous recombination (IHR) to produce the
recombinant virus. Since the viral swarm generated by IHR did
not show efﬁcient replication in PtM primary cells, we conducted
in vitro serial passages of the virus. Thus, we successfully gener-
ated a viral swarm that exhibited an enhanced replication capacity
in PtM cells and established infection in PtMs with high peak
viremia comparable to the currently available monkey-tropic
HIV-1 derivatives.
Results
Generation of a new HIV-1mt carrying CCR5-tropic subtype C env
through IHR
We employed IHR to generate recombinant viruses (Fujita et al.,
2013). First, we prepared DNA fragments by polymerase chain
reaction (PCR) ampliﬁcation of a region spanning the 50 long
terminal repeat (LTR) to upstream of the V1/V2 region in env
(nucleotide positions 1–6784 based on HXB2 numbering; acces-
sion number: K03455) using the plasmid DNA template encoding
the full-length NL-DT5R proviral genome (fragment I in Fig. 1A).
This fragment encodes a CypA-binding motif derived from the
corresponding sequence of SIVmac239 to evade restriction from
macaque TRIM5α, and the entire SIVmac239 vif gene to counteract
the macaque APOBEC3G. Second, a region spanning the vpr gene
to the R region of the 30 LTR (nucleotide positions 5558–9625
based on HXB2 numbering) was ampliﬁed from the HIV-1
97ZA012 strain (fragment II in Fig. 1B). To increase the possibility
to obtain a virus that can replicate in monkeys well, we thought
that it was better to generate swarm viruses having variation
without cloning. Resultant recombinant virus might fail to repli-
cate normally if recombination occurred between fragments I
and II that resulted in the 50 LTR of subtype B and the 30 LTR of
subtype C. The discordance of the 30 and 50 LTR may disrupt
successful translocation of the minus strand strong stop DNA to
the plus strand genomic RNA during reverse transcription (Goff,
2007). To match the sequence of the 30 LTR to that of the 50 LTR, we
prepared a third DNA fragment encoding a region spanning the 50
LTR to the middle of gag (nucleotide positions 1–1433 based on
HXB2 numbering) from the proviral DNA extracted from HIV-1
97ZA012-infected cells (fragment III in Fig. 1B). Fragments I and II
Fig. 1. Schematic representation of the genome organization of human immuno-
deﬁciency virus (HIV)-1 and monkey-tropic HIV-1 (HIV-1mt). Genome organiza-
tions of NL-DT5R (A), subtype C HIV-1 97Z012 (B) and HIV-1mt ZA012-P0 (C) are
depicted. The horizontal line represents DNA fragments I, II and III, used for
intracellular homologous recombination. Fragment I encodes a region from the 50
LTR to env of NL-DT5R plasmid DNA. Fragment II encodes a region from the
initiation of vpr to the R region of the 30 LTR of the HIV-1 97ZA012 strain. Fragment
III encodes a region from the 50 LTR to upstream of the cyclophilin A-binding motif
of the virus. Sequences from NL4-3 (open box), HIV-1 97ZA012 (ﬁlled box) and the
SIVmac239 genome (diagonally striped box) are depicted. The gray box in HIV-1mt
ZA012-P0 represents a gene that was not identiﬁed by direct sequence analysis.
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had an overlapping region between the initiation of vpr to
upstream of the env V1/V2 region, and fragments I and III had
an overlapping region between the 50 LTR to upstream of the
CypA-binding site.
These ampliﬁed DNA fragments (fragments I, II and III) were
co-transfected into C8166-CCR5 cells that are permissive to CCR5-
tropic HIV-1. On day 8 post-transfection, we observed the formation
of virus-induced cytopathic effects (CPEs), indicating the generation
of replication-competent recombinant virus. The new recombinant
virus was isolated and designated HIV-1mt ZA012-P0.
To determine the genomic organization of HIV-1mt ZA012-P0,
we subjected the viral RNA isolated from the culture supernatant
to direct sequencing. We found that the virus carried sequences of
the U5 region of the 50 LTR, gag, pol and vif derived from NL-DT5R
and sequences of 30 half of env, nef, and R and the U3 region of the
30 LTR derived from 97ZA012 (Fig. 1C). First, the recombination
breakpoint derived from fragments I and III was found to be
located within the junction between the U5 and R region of the 50
LTR (nucleotide positions 551–605 based on HXB2 numbering).
However, additional recombination breakpoints between frag-
ments I and II, encoding the vpr–env region, were not identiﬁed
due to multiple peaks at the same locations in the analyzed
sequence chromatograms. This result suggested that HIV-1mt
ZA012-P0 represented a swarm that might contain several variants
with various recombination breakpoints.
Increased replication competence of HIV-1mt ZA012 through
long-term in vitro passage in CD8þ cell-depleted pig-tailed macaque
peripheral blood mononuclear cells (PBMCs)
We subsequently determined whether HIV-1mt ZA012-P0
replicates in CD8þ cell-depleted pig-tailed macaque peripheral
blood mononuclear cells (PtM PBMCs), in which the parental
NL-DT5R replicated as described previously (Kamada et al.,
2006). HIV-1mt ZA012-P0 from the culture supernatant of
C8166-CCR5 was used to spinoculate CD8þ cell-depleted PtM
PBMCs, and the virion-associated reverse transcriptase (RT) activ-
ity was monitored in the culture supernatant (Fig. 2); however, no
RT activity was detected in the culture supernatant after passage 1
(Fig. 2).
Next we carried out in vitro serial passages to improve the
replication competence of the virus as observed in the cases of
HIV-1 (Freed and Martin, 1996; Willey et al., 1988). Infected cells
were co-cultured with freshly prepared CD8þ cell-depleted PtM
PBMCs every 1 or 2 weeks. Although detectable RT activity was not
observed during 10 successive passages (passage 1–10), a low level
of viral replication was conﬁrmed by the CPEs of C8166-CCR5 cells
co-cultured with PBMCs taken from the passage (data not shown).
A detectable peak of viral replication (319 cpm/μL) was observed
at 115 days after the ﬁrst inoculation (passage 11), and replication
was maintained following passages, eventually resulting in
enhanced replication in PtM PBMCs (1900 cpm/μL in passage 19).
The resultant virus, isolated from the culture supernatant of passage
19, was designated HIV-1mt ZA012-P19.
To evaluate the replication capacity of the virus, the replication
kinetics of HIV-1mt ZA012-P19 were compared to those of the
parental NL-DT5R and HIV-1mt ZA012-P0. Each viral stock was
normalized by the number of infectious units per cell (in this case,
a multiplicity of infection (MOI) of 0.1) and used to inoculate CD8þ
cell-depleted PtM PBMCs isolated from two donor monkeys;
virion-associated RT activity in the culture supernatant was
monitored daily (Fig. 3). Although HIV-1mt ZA012-P19 exhibited
a lower level of viral replication compared to that of SIVmac239,
the virus showed more efﬁcient replication than NL-DT5R and
HIV-1mt ZA012-P0 in cells from both animals. Therefore, we
successfully improved the replication capacity of the new HIV-
1mt in PtM PBMCs by in vitro passaging.
Sequence analysis of HIV-1mt ZA012-P0 and ZA012-P19
It is likely that HIV-1mt ZA012-P0 acquired genetic changes
and evolved to HIV-1mt ZA012-P19 through the serial passages in
PtM PBMCs. To compare the genomic sequence of these viruses,
we ﬁrst performed single genome ampliﬁcation (SGA) of viral RNA
isolated from the culture supernatant to determine the nucleic
acid sequences of the vpr–env region (nucleotide positions 5559–
8795 based on HXB2) of HIV-1mt ZA012-P0. Subsequently, we
identiﬁed the sequence of the region containing the expected
recombination breakpoints generated by IHR between fragments I
and II. Genetic analysis of 17 SGA clones revealed that these
sequences had NL-DT5R sequences in the 50 end and HIV-1
97ZA012 sequences in the 30 end, with seven different recombination
Fig. 2. Improved replication of HIV-1mt ZA012 throughout in vitro passages in
CD8þ cell-depleted PtM peripheral blood mononuclear cells (PBMCs). HIV-1mt
ZA012-P0 was used to spinoculate CD8þ cell-depleted PtM PBMCs, and virion-
associated RT activity in the culture supernatant was monitored daily. Some of the
infected cells were co-cultured with freshly prepared CD8þ cell-depleted PtM
PBMCs. One period of passage was indicated in the shaded grey or white zones. The
dotted line indicates data not available.
Fig. 3. Growth kinetics of HIV-1mt ZA012 in CD8þ cell-depleted PtM PBMCs. Growth kinetics of HIV-1mt ZA012-P0, HIV-1mt ZA012-P19, SIVmac239 and
NL-DT5R were compared in PBMCs from two PtMs. Each virus was used to spinoculate CD8þ cell-depleted PtM PBMCs (MOI¼0.1 TCID50 per cell), and the virion-
associated RT activity in the culture supernatant was monitored. The ﬁgure shown is representative of four independent experiments.
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breakpoints in the region (Fig. 4). One recombination breakpoint was
detected at nucleotide positions 178–187 of the vpr gene in 1/17 SGA
sequences (5736–5745 in HXB2 numbering, recombination type R1)
with 10 identical base pairs between NL-DT5R and 97ZA012.
In addition to R1, we identiﬁed the following recombination types:
the vpr gene in 3/17 SGA sequences (5760–5767; R2), the initiation of
tat in 2/17 SGA sequences, (5821–5839; R3), the end of the vpr gene
in 1/17 SGA sequence (5852–5865; R4), the initiation of rev in 6/17
SGA sequences (5960–6000; R5), the end of the vpu gene in 1/17 SGA
sequence (6357–6392; R6) and the upstream of V1/V2 of the env
gene in 3/17 SGA sequences (6467–6491; R7). These results suggest
that homologous recombination occurs in various sites with homo-
logous sequences.
Next, seven SGA sequences were ampliﬁed from viral RNA
isolated from the culture supernatant of PtM PBMCs infected with
HIV-1mt ZA012-P19, and nucleotide sequences and recombination
breakpoints were determined in the same manner. Unexpectedly,
all the sequences of HIV-1mt ZA012-P19 had three recombination
breakpoints in the region from the vpr to env genes (recombina-
tion type R8 in Fig. 4). The ﬁrst breakpoint was located in the vpr
gene (5760–5767), the second was located in the vpu gene (6194–
6213), and the third was located in env (6467–6491) with the
N-terminal portion of C1 region from NL4-3 sequence. Although
the pattern of recombination breakpoint of the virus differed from
those of HIV-1mt ZA012-P0, the ﬁrst and third recombination
breakpoints were identical to the recombination type of R2 and R7,
respectively (Fig. 4). It is likely that HIV-1mt ZA012-P19 was
generated from further recombination events that occurred in
the middle of the vpu gene (6194–6213) between recombination
type R2 and R7 of HIV-1mt ZA012-P0.
It is conceivable that the genome of HIV-1mt ZA012-P19
acquired several amino acid mutations associated with the
enhanced replication in PtM PBMCs. Compared with the deduced
amino acid sequences in HIV-1mt ZA012-P0, HIV-1mt ZA012-P19
acquired substitutions from Lys to Arg at amino acid position 432
in Pol-RT and Asp to Glu at position 232 in Pol-IN that were in the
NL-DT5R backbone. In addition, an amino acid substitution from
Phe to Ser at 139 in Nef was found in HIV-1mt ZA012-P19
compared to 17 SGA sequences derived from HIV-1mt ZA012-P0.
No nonsynonymous substitutions were identiﬁed in Gag and Vif,
the proteins responsible for evading TRIM5α and APOBEC3.
Around the recombination break points in HIV-1mt ZA012-P19,
the vpr and vpu genes keep each open reading frame and do not
contain any mutations in the region derived from NL-DT5R,
respectively. Furthermore, consensus amino acid sequence of
HIV-1mt ZA012-P0 and -P19 were also identical in the regions
derived from HIV-1 97ZA012, respectively. These facts suggest that
recombination was occurred to keep these genes intact.
Phylogenetic analysis of env genes
It is likely that HIV-1mt ZA012-P0 generated by IHR in human
C8166-CCR5 cells was a swarm carrying diverse env sequences of
the parental HIV-1 97ZA012, which evolved to HIV-1mt ZA012-P19
through in vitro passages. To evaluate the env variants selected in
C8166-CCR5 cells or primary PtM cells, we determined 22
sequences of HIV-1 97ZA012, 17 sequences of HIV-1mt ZA012-P0
Fig. 4. Recombination breakpoints in HIV-1mt ZA012-P0 and ZA012-P19 genomes.
The genome organizations of HIV-1mt ZA012-P0 and HIV-1mt ZA012-P19 are
schematically represented (upper two diagrams). The region from the initiation of
vpr to the end of env that included recombination breakpoint sites is depicted in the
third diagram; the HIV-1mt ZA012-P0 (17 SGA sequences) or HIV-1mt ZA012-P19
(seven SGA sequences) are depicted (bottom). Sequences from HIV-1mt ZA012-P0
were classiﬁed into seven patterns of recombination breakpoints (R1 to R7).
Sequences from HIV-1mt ZA012-P19 were classiﬁed into one recombination break-
point pattern (R8). The numbers (left) indicate the numbers of sequences per
analyzed sequence.
Fig. 5. Phylogenic analysis of partial env sequences. A neighbor-joining phylogenic
tree was constructed from the partial nucleic acid sequences of env (nucleotide
positions 211–2571 based on env of HXB2 numbering). The sequences of HIV-1
97ZA012 (white circle), HIV-1mt ZA012-P0 (grey circle) and HIV-1mt ZA012-P19
(black circle) were determined from SGA sequences. HIV-1 97ZA012 (accession
number: AF286227) and 98CN007 (AF286230) reference sequences were obtained
from the Los Alamos HIV sequence database (http://hiv-web.lanl.gov/). R1–R8
correspond to the patterns of recombination breakpoint types in Fig. 2. Bootstrap
values were computed from 1000 bootstrap replicates, and only 490% are shown
at branches. The scale bar indicates the substitutions per site.
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and seven sequences of HIV-1mt ZA012-P19 from SGA. Next, we
conducted a phylogenetic analysis of the nucleotide sequences of
the 30 terminal 2361 bp of each viral env derived from HIV-1
97ZA012 and shared by all variants of HIV-1mt ZA012-P0 and -P19
(Fig. 5). These sequences were divided into two clusters: the larger
cluster included 19 sequences of HIV-1 97ZA012, 8 sequences of
HIV-1mt ZA012-P0 and 7 sequences of HIV-1mt ZA012-P19; and
the smaller cluster included 3 sequences of HIV-1 97ZA012 and
9 sequences of HIV-1mt ZA012-P0. Recombination types R2, R3, R5
and R7 (Fig. 4) were intermingled among the sequences of the two
groups, suggesting that homologous recombination could occur in
various env templates.
To compare the genetic diversity of env in these viruses, we
computed the mean of all pair-wise distances between any two
viral env sequences in each of the viruses. The computed diversity
of env in HIV-1mt ZA012-P0 was 0.003870.0025 (7standard
deviation, SD), which was signiﬁcantly lower than that in the
parental HIV-1 97ZA012 (0.004470.0021; po0.05). The com-
puted diversity of HIV-1mt ZA012-P19 env was 0.001270.00078,
which showed signiﬁcantly lower variation compared to HIV-1mt
ZA012-P0 (po0.0001).
Co-receptor usage of HIV-1mt ZA012-P19
To characterize co-receptor usage of HIV-1mt ZA012-P19 after
long-term in vitro passage, we conducted an entry assay using
TZM-bl cells with small molecule antagonists (Fig. 6). Viral
infectivity of the CXCR4-tropic virus (NL4-3) was reduced in the
presence of an increasing amount of the CXCR4 inhibitor,
AMD3100, but was not affected by the CCR5 inhibitor, AD101.
In contrast, the CCR5-tropic virus, SIVmac239, was inhibited in the
presence of an increasing amount of AD101 but not by AMD3100.
Similar to the results using SIVmac239, HIV-1mt ZA012-P19
exhibited sensitivity to inhibition by AD101 but resistance to
AMD3100, indicating that the virus maintained its CCR5-tropism
after the serial passage.
Replication of HIV-1mt ZA012 in pig-tailed macaques
Since HIV-1mt ZA012-P19 utilized CCR5 as a co-receptor and
exhibited increased infectivity to primary cells of PtMs, we next
assessed the in vivo replication capacity of the virus by experi-
mental infection of PtMs. Two PtMs were inoculated intravenously
Fig. 6. Co-receptor usage of HIV-1mt ZA012-P19. Infectivity of HIV-1 NL4-3, SIVmac239 and HIV-1mt ZA012-P19 to TZM-bl cells was assessed in the presence of increasing
amounts of AMD3100 (CXCR4 inhibitor), AD101 (CCR5 inhibitor) or both. The experiment was conducted in triplicate.
Fig. 7. HIV-1mt ZA012 infection of pig-tailed macaques. Two pig-tailed macaques
were inoculated intravenously with HIV-1mt ZA012 (100,000 TCID50), and the
plasma viral RNA burdens (A) and circulating CD4þ T-lymphocytes (B) were
monitored.
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with 1.0105 TCID50 of the HIV-1mt prepared in PtM PBMCs, and
plasma viral RNA burdens and the numbers of circulating CD4þ
T-lymphocytes were monitored periodically (Fig. 7A). Plasma viral
RNA loads in PtM01 peaked (1.0106 copies/mL) at 2 weeks post-
infection (wpi) and declined thereafter to levels below the detec-
tion limit at 8 wpi. PtM02 exhibited a peak plasma viral RNA
burden (2.3106 copies/mL) at 1.5 wpi and maintained more than
1104 copies/mL by 9 wpi, but the viral load declined to levels
below the detection limit at 16 wpi. The numbers of CD4þ
T-lymphocytes in the circulation in both animals were not affected
(Fig. 7B). Furthermore, we analyzed naive and memory popula-
tions of CD4þ T cells and no preferential depletion of circulating
memory CD4þ T-lymphocyte was observed (data not shown).
Discussion
In this study, we used IHR to generate a new HIV-1mt carrying
env from the CCR5-tropic subtype C HIV-1 clinical isolate. This
recombination method has been used to generate infectious HIV-1
or SHIV by joining two linear DNAs in regions with completely
identical sequences (Chen et al., 2000; Kalyanaraman et al., 1988;
Kellam and Larder, 1994; Luciw et al., 1995; Srinivasan et al., 1989;
Velpandi et al., 1991). Recently, we applied IHR to generate a
replication-competent SHIV carrying subtype C env that was
inserted within the env sequence of subtype B (Fujita et al.,
2013). Here, we utilized the same method to generate HIV-1mt
by replacing a coding sequence region from subtype B with that of
a primary isolate of subtype C and investigated recombination
breakpoints in detail by analyzing the sequences of the resultant
viruses. We found seven variants with different recombination
breakpoints that were located within overlapped sequences
between fragments I and II. These variants were selected as
replication-competent virus in C8166-CCR5 cells that maintained
their variability, suggesting that IHR events occur frequently in
cells co-transfected with DNA fragments. In addition, it appears
that the length of identical sequence of as short as 8 bp is
sufﬁcient for IHR (recombination type R2 in Fig. 4). Furthermore,
IHR is suggested to occur between various DNA templates, based
on the phylogenetic analysis results that indicated intermingled types
of recombination breakpoints among different env sequences.
To develop a virus that efﬁciently infects monkey cells, it is
important to choose an env that mediates efﬁcient entry to
macaque cells. The Env proteins in most A–D subtypes of HIV-1
clinical isolates from infected individuals during the acute phase of
infection do not mediate efﬁcient entry using macaque CD4
receptors (Humes et al., 2012). In a preliminary experiment in
C8166-CCR5 cells, we generated ﬁve strains of replication-
competent HIV-1mt carrying env from subtype C HIV-1 clinical
isolates, including 97ZA012, but only three were infectious to PtM
cells (data not shown). The generation of SHIV 97ZA012 that can
establish infection in rhesus macaques as described previously
(Fujita et al., 2013) also suggested that Env of HIV-1 97ZA012 can
generate recombinant viruses that are infectious to macaque cells.
The serial passage of HIV-1mt ZA012-P0 through PtM PBMCs
resulted in the loss of variants with recombination breakpoints
and led to the emergence of HIV-1mt ZA012-P19 variants with
shared uniform mosaic breakpoints not detected before the
passage (Fig. 4). It is possible that recombination type R8 was
generated through additional recombination events within homo-
logous sequences in the vpu region between variants with recom-
bination type R2 and R7 because recombinant breakpoints located
on vpr and env regions of the virus were identical to that of R2 and
R7, respectively. This possibility of recombination between R2 and
R7 is also supported by the previous ﬁnding that the AAAAA tract
within the putative site of recombination is a recombination
hotspot during reverse transcription because the sequence facil-
itates template switching by pausing and dissociation of reverse
transcriptase and results in frequent recombination (Quinones-
Mateu et al., 2002).
HIV-1mt ZA012-P19 acquired three amino acid substitutions
(K432R of Pol-RT, D232E of Pol-IN and F138S of Nef) through serial
passages in PtM PBMCs, but the biological signiﬁcance of these
mutations remains undetermined. It has been reported previously
that two amino acid substitutions (N222K and V234I) in the
C-terminus of Pol-IN of NL4-3 could augment replication of HIV-
1mt in cynomolgus macaque HSC-F and human MT4/CCR5 cells
(Nomaguchi et al., 2013). A D232E mutation observed in this study
was positioned near these two residues, which might be asso-
ciated with increased replication in primate cells.
HIV-1mt ZA012 established infection in PtMs with the peak
viremia reaching 1.0–2.3106 copies/mL at 1.5 or 2 wpi (Fig. 7).
In contrast, NL-DT5R exhibited low levels of replication in PtMs
(at most 3.5104 copies/mL at peak viremia) regardless of CD8þ
cell-depletion, as described previously (Igarashi et al., 2007).
Plasma viral RNA load at peak viremia in HSIV-vif infected new-
born PtMs showed 0.5–1.0105 copies/mL (Thippeshappa et al.,
2011). The highest peak viral level has been achieved by stHIV-1
infection of PtMs, reaching 1.0105–106 copies/mL at the peak
(Hatziioannou et al., 2009). Although HIV-1mt ZA012 failed to
persist its replication over 10 weeks, the replication capacity of the
virus in the acute phase appeared to be comparable to or greater
than known monkey-tropic HIV-1 isolates. The caveat is that HIV-
1mt ZA012 was obtained through “autologous” cell passage.
The derivative of NL-DT5R was designed to counteract or evade
restrictions by macaque TRIM5α and APOBEC3G but not by
interferon (IFN)-stimulated genes (ISGs). One of the IFNα-
inducible host factors, tetherin, inhibits release of viral particles
from infected cells (Neil et al., 2008). HIV-1 Vpu is able to
counteract human tetherin activity but fails to downregulate this
activity in macaque (Jia et al., 2009). On the other hand, unlike
HIV-1 HXB2 or NL4-3, some strains of HIV-1 appear to antagonize
macaque tetherin by its N-terminal transmembrane (TM) domain
of Vpu (Shingai et al., 2011). It has been reported that replication of
monkey-tropic HIV-1 could be controlled in macaque lymphocytes
treated with IFN-α (Bitzegeio et al., 2013; Thippeshappa et al.,
2013). Further investigations are required to determine whether
HIV-1mt ZA012-P19 that encodes the N-terminal TM domain of
Vpu, Env and Nef from subtype C could efﬁciently replicate in the
presence of PtM tetherin or ISGs.
We generated the ﬁrst CCR5-tropic HIV-1mt in the currently
available derivatives of HIV-1 that can establish infection in
macaques. NL-DT5R, HSIV-vif and stHIV-1 are infectious to PtMs,
but these viruses are CXCR4 or CXCR4/CCR5 dual tropic. Several
monkey-tropic HIV-1 isolates carrying CCR5-tropic env have been
reported, but the viral replication was less efﬁcient than NL-DT5R
(Yamashita et al., 2008). The CCR5-tropic viruses preferentially
infect memory CD4þ T-lymphocytes and efﬁciently replicate in
effector sites in vivo (i.e., lymphocytes in the lung or gastrointest-
inal tract) (Brenchley et al., 2004; Mehandru et al., 2004; Okoye
et al., 2007; Picker et al., 2004). Although we characterized
co-receptor usage of HIV-1mt ZA012-P19 in vitro, further investi-
gation is needed to determine whether the virus behaves similarly
to CCR5-tropic HIV-1 isolates in patients in vivo.
In this study, we generated a new monkey-tropic HIV-1. The viral
swarm HIV-1mt ZA012-P19 carries env sequences from CCR5-tropic
subtype C HIV-1, and it successfully established infection in PtMs
with a high peak viremia comparable or greater than the monkey-
tropic HIV-1 strains currently available. Although the monkey-tropic
HIV-1 requires further adaptation to improve its in vivo replication
capacity, the virus potentially serves as a nonhuman primate model
for AIDS, which reproduces infectionwith currently circulating HIV-1.
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Materials and methods
Cells
293 T cells (DuBridge et al., 1987) were maintained in Dulbecco's
Modiﬁed Eagle Medium (D-MEM; Wako, Osaka, Japan) supplemen-
ted with 10% (vol/vol) fetal bovine serum (FBS; HyClone Labora-
tories, Logan, UT) and 1 mM L-glutamine. TZM-bl cells (Platt et al.,
1998) from the NIH AIDS research and reference reagent program
were maintained in D-MEM supplemented with 10% FBS, 1 mM
L-glutamine and 1 mM sodium pyruvate. The human T-cell line,
C8166-CCR5 (Shimizu et al., 2006) was maintained in Rosewell Park
Memorial Institute 1640 medium (RPMI-1640; Invitrogen, Carlsbad,
CA) supplemented with 10% FBS. PtM PBMCs from uninfected
monkeys were isolated using the ﬁcoll density gradient separation
method. For this procedure, a mixture of 95% lymphocyte separa-
tion medium (Wako) and 5% phosphate buffered saline (PBS) was
used as a separation solution as described previously (Agy et al.,
1992; Frumkin et al., 1993). Residual erythrocytes were lysed in ACK
lysing buffer (0.15 M NH4Cl, 10 mM KHCO3, 1.0 mM EDTA Na2).
Depletion of CD8þ cells was conducted with the magnetic-activated
cell sorting (MACS) system (Miltenyi Biotec, Gladbach, Germany).
Brieﬂy, isolated PtM PBMCs were stained with phycoerythrin (PE)-
conjugated anti-CD8 antibodies (clone SK1, BD Biosciences, San Jose,
CA) and then labeled with anti-PE MicroBeads (Miltenyi Biotec).
CD8þ cells were removed using a magnetic column according to the
manufacturer's instructions. PBMCs were cultured in RPMI-1640
supplemented with 10% FBS, 2 mM sodium pyruvate, 2 mM L-
glutamine, 50 nM 2-mercaptoethanol and 40 μg/mL gentamicin.
PBMCs were stimulated with 25 μg/mL Concanavalin A (conA) for
20 h and then cultured in the presence of 160 U/mL human recom-
binant interleukin-2 (IL-2; Wako).
Viruses
A stock of NL-DT5R virus was prepared from C8166-CCR5 cells
transfected with a plasmid encoding full-length proviral DNA of
NL-DT5R (pNL-DT5R) using the DEAE-Dextran/osmotic shock
procedure (Takai and Ohmori, 1990). SIVmac239 (Kestler et al.,
1988) stock virus was prepared from the culture supernatant of
293 T cells transfected with a plasmid encoding full-length
proviral DNA of SIVmac239 with Lipofectamine (Invitrogen).
CCR5-tropic subtype C HIV-1 clinical isolates including 97ZA012
were obtained from the NIH AIDS research and reference reagent
program.
Generation of recombinant virus through intracellular homologous
recombination
To generate recombinant virus by IHR, overlapping viral geno-
mic DNA fragments were prepared by PCR ampliﬁcation. A region
spanning the 50 LTR to env was ampliﬁed from pNL-DT5R (Gen-
Bank accession number: AB266485) using the HIV-1-U3-NotI-F
forward primer (50-ATGCGGCCGCTGGAAGGGCTAATTTGGTCC-
CAAAG-30; nucleotide positions 1–25 in NL-DT5R, and additional
NotI site sequences) and the env-2R reverse primer (50-CACA-
GAGTGGGGTTAATTTTACAC-30; nucleotide positions 6761–6784 in
NL-DT5R). PCR was conducted with Expand long-range dNTPack
(Roche Diagnostic, Basel, Switzerland). PCR conditions were as
follows: 94 1C for 2 min followed by 10 cycles of 94 1C for 15 s,
55 1C for 30 s and 68 1C for 8 min, 25 cycles of 94 1C for 15 s, 55 1C
for 30 s, 68 1C for 8 min, with 20 s increments at 68 1C for each
successive cycle and a ﬁnal elongation period of 68 1C for 7 min
(fragment I in Fig. 1A). Ampliﬁcation of a DNA fragment spanning
the initiation of vpr to the 30 LTR was derived from subtype C HIV-
1 clinical isolates of the HIV-1 97ZA012 strain. Viral RNA was
isolated from culture supernatant using a QIAamp viral RNA mini
kit (Qiagen, Hilden, Germany). Complementary DNA (cDNA) was
synthesized with Super Script III ﬁrst-strand synthesis SuperMix
(Invitrogen) using the OFM19-R reverse primer (50-AGGCAAGCTT-
TATTGAGGCTTA-30; nucleotide positions 9604–9625 based on the
HXB2 numbering). PCR ampliﬁcation of the viral cDNA was
conducted using HIV-1vpr-F forward primer (50-AGATGGAA-
CAAGCCCCAGAAGA-30; nucleotide positions 5558–5579 in the
HXB2 numbering) and OFM19-R reverse primer with the same
conditions (fragment II in Fig. 1A). To prepare a fragment spanning
the initiation of 50 LTR to the MA region of gag, proviral DNA was
extracted from proviral DNA of subtype C HIV-1 isolate-infected
C8166-CCR5 cells using DNeasy Blood & Tissue kits (Qiagen). The
following ampliﬁcation was conducted using HIV-1cladeC-U3-
NotI-F forward primer (50-ATGCGGCCGCTGGAAGGGTTAATTTACT-
CAAGAG-30; nucleotide positions 1–24 in the HXB2 numbering
plus NotI site sequences) and the PreSCA-R reverse primer
(50-AATCTATCCCATTCTGCAGC-30; nucleotide positions 1433–1414
in the HXB2 numbering) (fragment III in Fig. 1A). The PCR products
were puriﬁed using QIAquick PCR puriﬁcation kits (Qiagen).
Recombinant viruses were generated by means of IHR in the
cell. PCR-ampliﬁed linear viral DNA fragments were co-transfected
into C8166-CCR5 cells by the DEAE-dextran/osmotic shock proce-
dure (Takai and Ohmori, 1990). After transfection, cells were
maintained and passaged every 3 days. The culture supernatant
was harvested upon observation of virus-induced CPE.
Virus titration
The infectious titer of the viruses was deﬁned as the median
tissue culture infectious dose (TCID50) in TZM-bl cells as described
previously (Li et al., 2005). Four-fold, serially diluted viral stock
was used to inoculated TZM-bl cells (5000 cells per 200 μL of
growth medium containing DEAE-Dextran at a ﬁnal concentration
of 12.5 μg/mL) in quadruplicate in ﬂat-bottom 96-well plates. After
incubation for 48 h at 37 1C, the culture supernatant was removed
and the cells were treated with 50 mL of Cell lysis solution (Toyo-
Inki, Tokyo, Japan) for 15 min at room temperature with shaking.
Then, 30 mL of the cell lysate were transferred to F96 MicroWell
plates (Thermo Fisher Scientiﬁc, Roskilde, Denmark), and the
relative luminescence units (RLU) after adding 50 mL of luciferase
substrate (PicaGene, Toyo-Inki) to each well was determined using
a microplate reader (Mithrus LB940, Berthold Technologies, Bad
Wildbad, Germany). Viral infectivity was measured in RLUs, and
positive wells were deﬁned as RLU42background. The TCID50
was calculated as described previously (Reed and Muench, 1938).
Viral growth kinetics in pig-tailed macaque PBMCs
PtM PBMCs were isolated from two uninfected animals and
CD8þ cells were depleted as described above. Two days after
stimulation with Concanavarin A (25 mg/mL), 2.5105 cells of
CD8þ cell-depleted PtM PBMCs were inoculated with 2.5104
TCID50 of viral stocks by spinoculation (O’Doherty et al., 2000) at
1200g for 1 h at room temperature. After washing with PBS, the
infected cells in 200 μL of culture mediumwere cultured in round-
bottom 96-well plates at 37 1C. The upper 150 μL of culture
supernatant without aspirating cells in the bottom of the well
was exchanged with fresh medium everyday. The harvested
supernatant was stored at 20 1C prior to measure the activity
of RT associated with virions.
RT assay
The virion-associated RT activity in culture supernatant was
monitored as described previously (Willey et al., 1988). Brieﬂy,
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6 μL of culture supernatant were combined with 30 μL of RT
reaction cocktail [50 mM Tris–HCl, 75 mM KCl, 10 mM dithiothreitol,
4.95 mM MgCl2, 10 mg/mL polyA RNA, 5 mg/mL oligo-dT20, 0.05%
NP40] and 1.66104 Bq equivalent α32P-dTTP (PerkinElmer, Wal-
tham, Massachusetts, USA) and incubated at 37 1C for 2 h with gentle
agitation. Next, 3 μL of incubated mixture were blotted onto DE81
ion exchange cellulose paper (GE healthcare, Buckinghamshire, UK).
After four washes with 2 saline sodium citrate (SSC), the residual
radioactivity from synthesized DNA was counted using a liquid
scintillation counter.
Single genome ampliﬁcation (SGA)
SGA of the region spanning the initiation region of vpr to the
end of the env gene was conducted as described previously
(Salazar-Gonzalez et al., 2008). Synthesized viral cDNA was end-
point diluted and then subjected to nested-PCR. First-round PCR
was conducted with KOD-FX (TOYOBO, Osaka, Japan) in a total of
20 μL of reaction mixture, using the SGA-16F forward primer
(50-TGCAGCAGAGTAATCTTCCCACTACAGG-30; nucleotide positions
5260–5283 in NL-DT5R) and the SGA-OFM19R reverse primer
(50-AGGCAAGCTTTATTGAGGCTTAAGCAGTGG-30; 9771–9800 in
NL-DT5R). The ﬁrst-round PCR conditions were as follows: 94 1C
for 2 min, followed by 35 cycles of 98 1C for 10 s, 63 1C for 30 s and
68 1C for 5 min. Second-round PCR was performed using 1 μL of
the ﬁrst-round PCR product using the SGA-17F forward primer
(50-AGAAGAGACAATAGGAGAGGCCTTCGAATG-30; 5610–5639 in
NL-DT5R) and the SGA-2.5R reverse primer (50-AAAGCAGCTGCT-
TATATGCAGCATCTGAGG-30; 9673–9702 in NL-DT5R). The second-
round PCR conditions were the same as those in the ﬁrst-round
PCR. Ampliﬁcation of the target sequence was conﬁrmed with
agarose gel electrophoresis. According to a Poisson distribution,
when a positive ratio of ampliﬁcation from diluted cDNA is o30%
in multiple replicate PCR reactions, the amplicons are predicted
to be ampliﬁed from one-copy of template with the probability
of 480%. The single genome amplicons were puriﬁed before
sequence analysis.
Genomic analysis
Sequence analysis was performed using the BigDye terminator
v. 3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA)
and the ABI PRISM 3130xl genetic analyzer (Applied Biosystems).
The 30-terminal 2304 nucleotide sequences of env were aligned
using the Clustal X software (Thompson et al., 1997). A neighbor-
joining phylogenetic tree (Saitou and Nei, 1987) using Kimura's
two-parameter model (Kimura, 1980) was constructed using
MEGA 5 software (Tamura et al., 2011), and bootstrap values were
computed from 1000 bootstrap replicates (Felsenstein, 1985). Pair-
wise distances between any two nucleic acid sequences of the
30 terminal 2361 bp of each viral env within the parental HIV-1
97ZA012, HIV-1mt ZA012-P0 and HIV-1mt ZA012-P19 were calcu-
lated with Kimura's two-parameter model (Kimura, 1980) by using
MEGA 5 software (Tamura et al., 2011). The statistical signiﬁcance
between each viral pair-wise distance was calculated with Stu-
dent's t test using GraphPad Prism software (San Diego, CA, USA).
Co-receptor usage assay
Employing a previously reported method (Nishimura et al.,
2010) with minor modiﬁcations, co-receptor usage of viruses was
determined using the small molecule antagonists, AD101 (Trkola
et al., 2002) provided by Dr. Julie Strizki (Schering-Plough
Research Institute, Kenilworth, NJ) and AMD3100 (Sigma-Aldrich,
St. Louis, MO) (Donzella et al., 1998). Brieﬂy, freshly trypsinized
TZM-bl cells (5000 cells per 100 μL of growth medium containing
DEAE-Dextran at a ﬁnal concentration of 12.5 μg/mL) were seeded
in ﬂat-bottom 96-well plates. The cells were incubated with 50 μL
of co-receptor antagonists at ﬁnal concentrations ranging from
0.1 nM to 1000 nM for 1 h at 37 1C and inoculated with 100 TCID50
of replication-competent virus in triplicate. After incubation for
48 h at 37 1C, luciferase activity was measured, and the percent
infectivity relative to that measured in mock-treated wells was
determined.
Experimental infection of pig-tailed macaques with HIV-1mt ZA012
HIV-1mt ZA012 challenge stock was prepared from culture
supernatant of PtM PBMCs infected with HIV-1mt ZA012-P19. The
virus was titrated with PtM PBMCs as described previously (Fujita
et al., 2013). Two pig-tailed macaques, PtM01 and PtM02 aged
7 and 6 years, respectively, were intravenously inoculated with
1.0105 TCID50 of HIV-1mt ZA012. Plasma viral RNA loads were
measured with TaqMan real time RT-PCR as described previously
(Miyake et al., 2006) with minor modiﬁcations; RT-PCR was con-
ducted for HIV-1 vpr ampliﬁcation using the NM3rNvpr-F forward
primer (50-CAGAAGACCAAGGGCCACAG-30) and NM3rNvpr-R
reverse primer (50-GTCTAACAGCTTCACTCTTAAGTTCCTCT-30). PCR
products were detected with a labeled probe, NM3rNvpr-T
(50-Fam-AGGGAGCCATACAATGAATGGACACT-Tamra-30; Perkin Elmer).
Animal experiments were conducted in the biosafety level 3 animal
facility, in compliance with institutional regulations approved by the
Committee for Experimental Use of Nonhuman Primates of the
Institute for Virus Research, Kyoto University, Kyoto, Japan.
Flow cytometry
To enumerate CD4þ T-lymphocytes, and memory and naïve
CD4þ T-lymphocytes, whole blood samples were stained with
ﬂuorescently labeled mouse monoclonal antibodies. Anti-CD3
(clone SP34-2) conjugated with Paciﬁc Blue, anti-CD4 (clone
L200) conjugated with PerCP-Cy5.5, anti-CD8 (clone SK1) conju-
gated with APC-Cy7, anti-CD20 (clone L27) conjugated with FITC
and anti-CD95 (clone DX2) conjugated with APC were purchased
from BD Biosciences, and anti-CD28 (clone CD28.2) conjugated
with PE was purchased from eBioscience (San Diego, CA).
CD28highCD95lowCD4þ or CD28high/lowCD95highCD4þ T-cell subsets
were considered as naïve or memory CD4þ T-lymphocytes, respec-
tively (Pitcher et al., 2002). The absolute number of lymphocytes in
the blood was determined using an automated hematology analy-
zer, KX-21 (Sysmex, Kobe, Japan).
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